Last reviewed · How we verify
Allogeneic hMSCs
At a glance
| Generic name | Allogeneic hMSCs |
|---|---|
| Also known as | Biosense Webster MyoStar NOGA Injection Catheter System., Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) |
| Sponsor | Joshua M Hare |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) (PHASE1)
- Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression. (PHASE1, PHASE2)
- Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines (PHASE1)
- Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (PHASE1, PHASE2)
- Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (PHASE2)
- Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD) (PHASE1, PHASE2)
- Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogeneic hMSCs CI brief — competitive landscape report
- Allogeneic hMSCs updates RSS · CI watch RSS
- Joshua M Hare portfolio CI